Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02980926 · ClinicalTrials.gov registry record · Phase 4
Mepivacaine vs. Bupivacaine Spinal Anesthetic in Total Knee Arthroplasty
A Phase 4 study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT02980926 is a Phase 4 study that has completed, run by Henry Ford Health System. The registered enrollment target is 32 participants.
The verdict
NCT02980926, a Phase 4 study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a shorter-acting spinal anesthetic called mepivacaine has advantages over a longer-acting medication called bupivacaine.
Interventions
- DRUG Bupivacaine
- DRUG Mepivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-12 |
| Est. Completion | 2017-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02980926
The ClinicalTrials.gov registry entry for NCT02980926 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine is the first listed.
NCT02980926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02980926 about?
NCT02980926 is a clinical study titled "Mepivacaine vs. Bupivacaine Spinal Anesthetic in Total Knee Arthroplasty". The purpose of this study is to determine if a shorter-acting spinal anesthetic called mepivacaine has advantages over a longer-acting medication called bupivacaine.
What is the current status of trial NCT02980926?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2016-12. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02980926?
The interventions under investigation include: Bupivacaine (DRUG), Mepivacaine (DRUG).
Who is sponsoring clinical trial NCT02980926?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.